These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1181 related items for PubMed ID: 19318984

  • 1. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS, Poulter NR, Dahlof B, Wedel H, ASCOT Investigators.
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Coronary heart disease benefits from blood pressure and lipid-lowering.
    Sever PS, Poulter NR, Mastorantonakis S, Chang CL, Dahlof B, Wedel H, ASCOT Investigators.
    Int J Cardiol; 2009 Jun 26; 135(2):218-22. PubMed ID: 19232755
    [Abstract] [Full Text] [Related]

  • 5. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
    Sever PS, Poulter NR, Dahlof B, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes G, Mehlsen J, Nieminen MS, O'Brien ET, Ostergren J, ASCOT Investigators.
    Eur Heart J; 2008 Feb 26; 29(4):499-508. PubMed ID: 18175773
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
    Sever PS.
    Am J Med; 2005 Dec 26; 118 Suppl 12A():3-9. PubMed ID: 16356801
    [Abstract] [Full Text] [Related]

  • 8. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
    Gupta A, Mackay J, Whitehouse A, Godec T, Collier T, Pocock S, Poulter N, Sever P.
    Lancet; 2018 Sep 29; 392(10153):1127-1137. PubMed ID: 30158072
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.
    Williams B, Lacy PS, Cruickshank JK, Collier D, Hughes AD, Stanton A, Thom S, Thurston H, CAFE and ASCOT Investigators.
    Circulation; 2009 Jan 06; 119(1):53-61. PubMed ID: 19103995
    [Abstract] [Full Text] [Related]

  • 11. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
    Poulter NR, Dobson JE, Sever PS, Dahlöf B, Wedel H, Campbell NR, ASCOT Investigators.
    J Am Coll Cardiol; 2009 Sep 22; 54(13):1154-61. PubMed ID: 19761936
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
    Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B, ASCOT investigators.
    Eur J Cardiovasc Prev Rehabil; 2005 Feb 22; 12(1):29-36. PubMed ID: 15703503
    [Abstract] [Full Text] [Related]

  • 13. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators.
    Drugs; 2004 Feb 22; 64 Suppl 2():43-60. PubMed ID: 15765890
    [Abstract] [Full Text] [Related]

  • 14. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT) Investigators.
    N Engl J Med; 2005 Apr 07; 352(14):1425-35. PubMed ID: 15755765
    [Abstract] [Full Text] [Related]

  • 15. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
    Dolan E, Stanton AV, Thom S, Caulfield M, Atkins N, McInnes G, Collier D, Dicker P, O'Brien E, ASCOT Investigators.
    J Hypertens; 2009 Apr 07; 27(4):876-85. PubMed ID: 19516185
    [Abstract] [Full Text] [Related]

  • 16. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
    Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.
    Diabetes Care; 2006 Jun 07; 29(6):1220-6. PubMed ID: 16731999
    [Abstract] [Full Text] [Related]

  • 17. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
    Tikkanen MJ, Holme I, Cater NB, Szarek M, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR, Incremental DEcrease through Aggressive Lipid Lowering Investigators.
    Am J Cardiol; 2009 Mar 01; 103(5):577-82. PubMed ID: 19231315
    [Abstract] [Full Text] [Related]

  • 18. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
    Koren MJ, Hunninghake DB, ALLIANCE Investigators.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1772-9. PubMed ID: 15519006
    [Abstract] [Full Text] [Related]

  • 19. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP, ALLIANCE Investigators.
    Am J Kidney Dis; 2009 May 02; 53(5):741-50. PubMed ID: 19216014
    [Abstract] [Full Text] [Related]

  • 20. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D, Park HJ, Ko SK.
    Clin Ther; 2009 Oct 02; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.